- Report Scope:
- Pipeline Assessment—regional breakdown
- Clinical Trials Assessment—trial breakdown by phase
- Commercial Assessment—leading marketed products, current and future players
- Competitive Landscape Analysis—key market events to 2026
53% of G/GEJAC clinical trials are located in the Asia-Pacific region, with 43% in Japan. The APAC region shows to be a considerable global lead in clinical activity, followed by North America.
Other key findings from this report include the approval of PD-(L)1 modulators is expected to transform the market in future.
As there are no screening programs for these cancers in most of the 8MM (with the exception of Japan) most cases of G/GEJAC are diagnosed at advanced stage, which has poor prognoses. The current G/GEJAC treatment landscape is still very dependent on chemotherapy.
Our Biosimilars market report provides an assessment of the pipeline, clinical, and commercial landscape. Stay ahead of the curve by getting a thorough understanding of the market.